The Situation
Mid-size biopharma company concerned about access implications of a high-priced specialty product
The Solution
EVERSANA research determined product’s value supported significantly higher price than initially planned, with minimal risk to access and uptake
The Results
- >4X increase to client’s original pricing assumption
- >$1B asset while facing minimal uptake obstacles